MAM
UTHR icon

Majedie Asset Management’s United Therapeutics UTHR Stock Holding History

Majedie Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-43,471
Closed -$5.59M – 72
2014
Q3 		$5.59M Buy
+43,471
New +$4.48M 0.95% 13

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Majedie Asset Management's UTHR Position: Q4 2014 in Review

Majedie Asset Management sold out of United Therapeutics (UTHR) in Q4 2014, closing a stake of 43,471 shares — an estimated $5.59M sold.

Majedie Asset Management first reported a position in UTHR in Q3 2014 and held it in 1 quarter. The position peaked at $5.59M in Q3 2014. 334 funds tracked by Wall St. Rank hold UTHR as of Q4 2014.

  • Majedie Asset Management reported no remaining United Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Majedie Asset Management sold 43,471 United Therapeutics shares in Q4 2014, an estimated $5.59M.
  • Majedie Asset Management first reported a position in United Therapeutics in Q3 2014 and held it in 1 quarter.
  • Majedie Asset Management's United Therapeutics position peaked at $5.59M in Q3 2014.
  • 334 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2014.

Based on Majedie Asset Management's 13F filing for Q4 2014, filed 4 Feb 2015.